TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases

Safety, pharmacokinetic, and pharmacodynamic data from healthy volunteers anticipated in 1H 2026 Designed to activate and expand tissue regulatory T cells (Tregs) without stimulating effector or innate immune cells, TRB-061 offers a potential new approach to immune modulation without broad immunosuppression South San Francisco, Calif., June 3, 2025 – TRex Bio, Inc. (“TRexBio”), a clinical-stage […] The post TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases appeared first on TrexBio .